GSK plc (LON:GSK) Receives GBX 2,048.57 Consensus PT from Brokerages

Posted by George Bondi on Sep 12th, 2026

GSK plc (LON:GSK – Get Free Report) has been assigned a consensus recommendation of “Hold” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is GBX 2,039.38.

A number of brokerages have issued reports on GSK. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a report on Wednesday, September 2nd. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 1,975 price objective on shares of GSK in a research note on Tuesday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 target price on shares of GSK in a report on Wednesday, July 29th.

Get Our Latest Stock Analysis on GSK

Insider Buying and Selling at GSK

In other GSK news, insider Vishal Sikka bought 1,266 shares of GSK stock in a transaction dated Monday, June 22nd. The shares were purchased at an average cost of GBX 5,069 per share, with a total value of £64,173.54. Also, insider Jeannie Lee bought 802 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average price of GBX 5,069 per share, with a total value of £40,653.38. Insiders acquired 3,625 shares of company stock valued at $13,494,563 in the last 90 days. Insiders own 0.20% of the company’s stock.

GSK Stock Performance

LON GSK opened at GBX 1,770.50 on Friday. The company has a 50-day simple moving average of GBX 1,901.77 and a two-hundred day simple moving average of GBX 1,968.13. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 103.36. GSK has a 12-month low of GBX 1,455 and a 12-month high of GBX 2,282. The firm has a market cap of £70.94 billion, a price-to-earnings ratio of 15.03, a PEG ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK – Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, equities analysts forecast that GSK will post 175.980975 EPS for the current year.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

Positive Sentiment: Japan’s Ministry of Health approved a prefilled, ready-to-use presentation of GSK’s Shingrix shingles vaccine. The format could improve convenience for healthcare providers and support Shingrix adoption in an important market. Japan MHLW approves GSK prefilled Shingrix presentation
Positive Sentiment: GSK is advancing its experimental mRNA seasonal flu vaccine into late-stage development after mid-stage results showed stronger immune responses than standard- and high-dose approved flu vaccines in younger and older adults. Success in late-stage trials could create a meaningful future growth opportunity, though clinical and regulatory risks remain. GSK mRNA flu vaccine development
Neutral Sentiment: Several GSK executives acquired small amounts of stock under the company’s reward plan, including Julie Brown’s purchase of seven shares worth approximately £126. The transactions signal alignment with shareholders but are too small to represent a major investment signal. GSK executives acquire shares
Neutral Sentiment: RBC reiterated its “Sector Perform” rating, indicating a balanced view rather than a strong bullish or bearish stance. Other brokerages have set an average target of about GBX 2,048.57, above the recent trading level. RBC reiterates GSK Sector Perform rating
Negative Sentiment: Commentary highlighting that GSK trades below levels seen decades ago reflects continuing investor concerns about valuation, growth expectations and the company’s ability to overcome past challenges. This sentiment may be weighing on the shares despite the positive vaccine developments. Analysis of GSK share price

GSK Company Profile

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.